Saturday, January 4, 2020, 12:00 AM - Monday, January 4, 2021, 11:58 PM

This enduring material was recorded from the live version.  

Gastroenterology, Nurse Practitioners, Nursing, Pharmacy, Physician Assistant, Primary Care, Topics of Interest, Inflammatory Bowel Disease (IBD)

1. Describe the current understanding of IBD pathophysiology with respect to inflammatory pathways and potential therapeutic agents
2. Evaluate the mechanisms of action and available efficacy and safety data surrounding new and emerging therapies for the treatment of IBD
3. Integrate the latest clinical data into current and future personalized therapeutic strategies for the management of IBD

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME). 

The University of Cincinnati designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

The University of Cincinnati, NACCME and Imedex are accredited by the ACCME to provide continuing medical education for physicians, and have collaborated to design and execute this live activity.

For accreditation purposes, the University of Cincinnati is responsible for certification and documentation of attendance for this activity.
The opinions expressed during the live activity are those of the faculty and do not necessarily represent the views of the University of Cincinnati. The information is presented for the purpose of advancing the attendees’ professional development.

The registration form for this activity Is currently unavailable.

No faculty are available for this activity at this time.

Janssen Pharmaceuticals, Inc

---

Keywords: